Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Status:
Completed
Trial end date:
2020-05-06
Target enrollment:
Participant gender:
Summary
This is a multicenter, international, double-blind study of the administration of mavacamten
in participants with symptomatic obstructive HCM (oHCM). Approximately 220 participants will
be randomized to receive placebo or mavacamten.